



HAL
open science

Impact of the first-line treatment shift from dihydroartemisinin/piperaquine to artesunate/mefloquine on *Plasmodium vivax* drug susceptibility in Cambodia

Camille Roesch, Mélissa Mairet-Khedim, Saorin Kim, Dysoley Lek, Jean Popovici, Benoit Witkowski

► To cite this version:

Camille Roesch, Mélissa Mairet-Khedim, Saorin Kim, Dysoley Lek, Jean Popovici, et al.. Impact of the first-line treatment shift from dihydroartemisinin/piperaquine to artesunate/mefloquine on *Plasmodium vivax* drug susceptibility in Cambodia. *Journal of Antimicrobial Chemotherapy*, 2020, 75 (7), pp.1766-1771. 10.1093/jac/dkaa092 . pasteur-03494789

HAL Id: pasteur-03494789

<https://pasteur.hal.science/pasteur-03494789>

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Impact of the first-line treatment shift from dihydroartemisinin/piperazine to artesunate/mefloquine on *Plasmodium vivax* drug susceptibility in Cambodia

Camille Roesch ^{1,2*}, MéliSSa Mairet-Khedim^{1,2}, Saorin Kim^{1,2}, Dysoley Lek³, Jean Popovici ^{1,2†} and Benoit Witkowski^{1,2†}

¹Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia; ²Malaria Translational Research Unit, Institut Pasteur, Paris & Institut Pasteur du Cambodge, Phnom Penh, Cambodia; ³National Center for Malariology, Entomology and Malaria Control, Phnom Penh, Cambodia

*Corresponding author. Email: roesch.camille@gmail.com

†These authors contributed equally.

Received 18 December 2019; returned 20 January 2020; revised 16 February 2020; accepted 20 February 2020

Background: Cambodia is the epicentre of the emergence of *Plasmodium falciparum* drug resistance. Much less is known regarding the drug susceptibility of the co-endemic *Plasmodium vivax*. Only *in vitro* drug assays can determine the parasite's intrinsic susceptibility, but these are challenging to implement for *P. vivax* and rarely performed.

Objectives: To evaluate the evolution of Cambodian *P. vivax* susceptibility to antimalarial drugs and determine their association with putative markers of drug resistance.

Methods: *In vitro* response to three drugs used in the past decade in Cambodia was measured for 52 clinical isolates from Eastern Cambodia collected between 2015 and 2018 and the sequence and copy number variation of their *pvmdr1* and *pvcr1* genes were analysed. *pvmdr1* polymorphism was also determined for an additional 250 isolates collected in Eastern Cambodia between 2014 and 2019.

Results: Among the 52 cryopreserved isolates tested, all were susceptible to the three drugs, with overall median IC₅₀s of 16.1 nM (IQR 11.4–22.3) chloroquine, 3.4 nM (IQR 2.1–5.0) mefloquine and 4.6 nM (IQR 2.7–7.0) piperazine. A significant increase in chloroquine and piperazine susceptibility was observed between 2015 and 2018, unrelated to polymorphisms in *pvcr1* and *pvmdr1*. Susceptibility to mefloquine was significantly lower in parasites with a single mutation in *pvmdr1* compared with isolates with multiple mutations. The proportion of parasites with this single mutation genotype increased between 2014 and 2019.

Conclusions: *P. vivax* with decreased susceptibility to mefloquine is associated with the introduction of mefloquine-based treatment during 2017–18.

Introduction

Malaria remains one of the most common infectious diseases in the world and the rapid selection of *Plasmodium falciparum* parasites resistant to antimalarial drugs is threatening control efforts. Southeast Asia has been the hotspot of the emergence of *P. falciparum* resistance against virtually all antimalarials used. Regarding *Plasmodium vivax*, inherent constraints associated with parasite biology limit the capacity to investigate this phenomenon. Indeed, *P. vivax* cannot be continuously cultivated *in vitro* and only tedious *in vitro* short-term cultures are

possible to determine the intrinsic susceptibility of the parasites. Besides, *P. vivax* parasites are typically asynchronous and multiple developmental stages can be present within an infected patient, which can affect the *in vitro* drug susceptibility of the parasites.¹ Therefore, drug efficacy for *P. vivax* is mainly evaluated through clinical studies that are confounded by a number of biases of host origin (immunity, drug adsorption, metabolism and so on) and parasite factors (reinfection and relapses).² Molecular markers of resistance are useful tools to rapidly assess changes in drug susceptibility within a given parasite

population. While widely used for the surveillance of *P. falciparum* resistance to many antimalarials, there are still no validated molecular markers of resistance for *P. vivax* clinical isolates. Candidate markers have been proposed in some studies and, notably, polymorphism, amplification or expression of *pvct* and *pvmdr1* are suspected to be involved in chloroquine and/or mefloquine resistance; however, formal evidence of their involvement in natural populations of *P. vivax* remains to be found.^{3–6}

The treatment for *P. vivax* malaria in Cambodia until 2012 was chloroquine. In order to provide a unified drug policy for all species, the treatment changed to a combination of dihydroartemisinin/piperazine in 2012. Following the emergence of *P. falciparum* resistance to piperazine, the first-line treatment for all malaria species changed again in 2016 to a combination of artesunate/mefloquine, which was gradually implemented in the country mid-2017. While the susceptibility of *P. falciparum* to these different antimalarials is continuously monitored, very few data exist concerning the response of *P. vivax*.

This study aimed to determine the *in vitro* susceptibility of parasites collected in Eastern Cambodia over 4 years to three antimalarials used in the country in the past decade and discover any association of *in vitro* phenotypes to polymorphisms in the *pvct* and *pvmdr1* genes.

Materials and methods

P. vivax clinical isolate collection

Samples were collected from symptomatic patients seeking treatment in Eastern Cambodia between 2014 and 2019. Venous blood was collected in EDTA tubes for molecular analysis and immediately stored at -20°C . Additionally, for *in vitro* assays a heparin tube was collected from which leucocytes were depleted using non-woven fabric (NWF) filters⁷ (Zhi Xing Bio S&T Co. Ltd, China) and RBCs were immediately cryopreserved in Glycerolyte 57 (Baxter Healthcare Corporation, USA) following published procedures.⁸

DNA extraction and PCR detection of *P. vivax*

DNA was extracted from 200 μL of whole blood using the QIAamp DNA Blood Mini Kit (QIAGEN, Courtaboeuf, France), according to the manufacturer's instructions. Molecular detection and identification of *Plasmodium* parasites were performed by real-time PCR as previously described.⁹

Drug plate preparation and *in vitro* susceptibility assay

P. vivax susceptibility to drugs was measured using a protocol modified from Suwanarusk *et al.*³ in which 96-well plates of drugs were prepared in advance and stored at -20°C . Chloroquine, mefloquine and piperazine [obtained from the WorldWide Antimalarial Resistance Network (WWARN)] were tested, each at eight different concentrations. Cryopreserved isolates associated with PCR-confirmed *P. vivax* mono-infection, containing more than 75% of ring stages determined by microscopy, were thawed and cultured into schizont stage (42–48 h) in Iscove's Modified Dulbecco's Medium (IMDM)-based medium following established protocols.^{8,10} Incubation was stopped when >40% of mature schizonts in the drug-free control wells was reached and thick blood films were stained with 5% Giemsa (Merck, Germany). The number of schizonts (>4 nuclei visible) per 300 asexual parasites (free merozoites and gametocytes excluded) was determined and normalized to the no-drug controls. IC_{50} values were determined using ICEstimator online software (<http://www.antimalarial-icestimator.net>).

Gene copy number determination of *pvmdr1* and *pvct*

The number of copies of *pvmdr1* and *pvct* was measured by quantitative PCR relative to the single-copy β -tubulin gene using a CFX96 real-time PCR instrument (Bio-Rad) (primers listed in Table 1). PCRs were conducted in 20 μL volumes in a 96-well plate containing $1 \times$ HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne, Tartu, Estonia), 0.5 μM each forward and reverse primers and 2 μL of template DNA. Amplifications were performed under the following conditions: 95°C for 15 min, followed by 45 cycles of 95°C for 15 s, 60°C for 20 s and 72°C for 20 s. The number of *pvmdr1* copies for each sample was measured in triplicate relative to a standard curve made of synthetic β -tubulin and *pvmdr1* genes, each cloned in a pEX-A2 vector (Eurofins Genomics, Greece) and mixed at different ratios from 1:1 up to 1:5 (one copy of β -tubulin and up to five copies of *pvmdr1*) (Table 1). The number of *pvct* copies for each sample was measured in triplicate relative to an

Table 1. List of primers and synthetic genes used for *pvct* and *pvmdr1* gene copy number determination and sequencing

Name	Sequence (5'→3')	Reference
Gene copy number determination		
<i>pvmdr1</i> synthetic gene	GCAACTCCATAAAGAACAACATCAAGTATAGTTTGTACAGCCTGAAAGATTTAGAAGCCTTATCGG AGGAGTCGAACGAAGATGGTTTTCTCTCAAA	this work
β -TubulinPv synthetic gene	CAGGAGTTACATGTTCTTAAGATTTCTGGTCAGTTAAATTCTGATTTGAGAAAATTAGCTGTCAATT TAATTCCTTCCCAAGACTCCATTTTTATGATTGGTTTTGCACCACTAACAAGCAGAGG	20
PvMDR1_F	GCAACTCCATAAAGAACAACATC	this work
PvMDR1_R	TTTGAGAAGAAAACCATCTTCG	this work
PvCRT_F	GGGAGTCCCAATAACCC	this work
PvCRT_R	GTTGTCTGCCACTCTCCTG	this work
CN_ β -tubulin_F	CATGTTCTGTTAAGATTTCTGGT	20
CN_ β -tubulin_R	GTTAGTGGTGCAAAACCAATCA	
Sequence polymorphism		
Pvmdr976 F	GGATAGTCATGCCCCAGGATTG	3
Pvmdr976 R	CATCAACTTCCCGCGTAGC	
Pvcrt-o F1 (sense)	AAGAGCCGTCTAGCCATCC	11
Pvcrt-o R3	AGTTTCCCTCTACACCCG	

internal calibrator control. The $\Delta\Delta\text{CT}$ method (where CT is the cycle threshold) was used to determine the number of copies in each sample.

Sequence polymorphism of *pvmdr1* and *pvcr1* genes

PCR and Sanger sequencing (Macrogen, Seoul, South Korea) were used to determine *pvmdr1* and *pvcr1* sequences using the following conditions. For *pvmdr1*, the PCR was conducted in 30 μL reactions consisting of 3 μL of DNA, 0.15 μM primers and 1 \times HOT FirePol Blend MasterMix (Solis BioDyne) under the following conditions: 94°C for 10 min, followed by 40 cycles of 94°C for 30 s, 64°C for 90 s, 72°C for 45 s and a final extension at 72°C for 10 min. For *pvcr1*, the PCR was conducted in 30 μL reactions consisting of 3 μL of DNA, 0.25 μM primers and 1 \times HOT FirePol Blend MasterMix under the following conditions: 94°C for 10 min, followed by 35 cycles of 94°C for 50 s, 65°C for 60 s, 72°C for 90 s and a final extension at 72°C for 10 min. Primers used are described in Table 1. Expected amplicon sizes are 604 bp and 1186 bp, respectively, for *pvmdr1* and *pvcr1*.^{3,11} Nucleotides and corresponding amino acids were analysed using MEGA 7 software (Beckman). The sequences generated were compared with AY571984.1 for *pvmdr1* and with AF314649.1 for *pvcr1*.

Statistical analysis

Comparison of mean of non-Gaussian data was done by the Mann-Whitney test. Multiple comparisons of means of non-Gaussian data were performed by Kruskal-Wallis and Dunn's *post hoc* tests. Proportions were compared by Fisher's exact test. All analyses were performed using GraphPad Prism (v7.00). A *P* value of <0.05 was considered significant.

Ethics

The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Ethics clearance for the samples used in this study was obtained from the Ministry of Health National Ethics Committee in Cambodia (364NECHR, 478NECHR, 270NECHR and 317NECHR). All patients or their parents/guardians provided informed written consent.

Results

Evolution of Cambodian *P. vivax* *in vitro* susceptibility to three antimalarials

The susceptibility of 52 *P. vivax* cryopreserved clinical isolates from Eastern Cambodia collected between 2015 and 2018 was assessed by a schizont maturation assay validated using susceptible and resistant strains of *P. falciparum* (Table S1, available as [Supplementary data](#) at JAC Online). The IC_{50} values for all 52 isolates were low and homogeneous for the three drugs, indicating the absence of high-grade resistant parasites. Median IC_{50} values of 16.1 nM (IQR 11.4–22.3), 3.4 nM (IQR 2.1–5.0) and 4.6 nM (IQR 2.7–7.0) were observed for chloroquine, mefloquine and piperazine, respectively (Figure 1).

The susceptibility data for the three drugs were analysed according to the time of collection of the isolates. While for mefloquine there was no significant difference in IC_{50} depending on the collection period, the response of parasites to chloroquine and piperazine was significantly different. The IC_{50} of chloroquine decreased between 2015–16 [median 20.7 nM (IQR 16.0–33.44)] and 2017–18 [median 14.3 nM (IQR 10.1–19.4), *P*=0.0023] in a

fashion similar to the IC_{50} of piperazine [median 6.7 nM (IQR 4.3–8.1) versus median 4.1 nM (IQR 2.6–5.3), *P*=0.0213].

Polymorphisms of *pvcr1* and *pvmdr1* and association with drug susceptibility of isolates

Sequences of *pvmdr1* were interpretable for the 52 cryopreserved isolates. All isolates had the T958M mutation. Two other mutations were detected: Y976F (in 28/52, 54% of isolates) and F1076L (in 45/52, 86.5% of isolates). Three different *pvmdr1* genotypes were observed, the most frequent being the triple T958M-Y976F-F1076L mutant (28/52, 54%), followed by the double T958M-F1076L mutant (17/52, 33%) and the single T958M mutant (7/52, 13%) (Table S2). All isolates with the Y976F mutation had also the F1076L mutation. No isolate had the WT *pvmdr1* Sal-1 sequence. Sequences of *pvcr1* were interpretable for 45 isolates, of which 69% (31/45) had a lysine insertion at codon 10 (K10_{insert}). In addition, two newly described mutations were observed, albeit at low frequency: one isolate (1/45, 2%) had an A107V mutation and four (4/45, 9%) an S163N mutation. Overall, four different *pvcr1* genotypes were detected, the most frequent being the K10_{insert} alone (noted as genotype 1, 27/45, 60%), followed by the Sal-1 WT (13/45, 29%), the K10_{insert}/S163N (genotype 2, 3/45, 7%) and one isolate (1/45, 2%) for each of the S163N (genotype 3) and K10_{insert}/A107V (genotype 4) genotypes. All isolates had a single copy of both *pvmdr1* and *pvcr1* genes.

The *in vitro* susceptibility of isolates to all drugs was analysed according to their polymorphisms in *pvmdr1* and *pvcr1*. IC_{50} values were compared between the different genotypes. Among all the *pvmdr1* and *pvcr1* polymorphisms, the only significant association was between *pvmdr1* and the response of isolates to mefloquine (Figure S1).

Multiple comparison analysis of the susceptibility to mefloquine between the three *pvmdr1* genotypes showed a significantly lower IC_{50} for the triple T958M-Y976F-F1076L mutants [median 2.9 nM (IQR 2.1–4.3)] compared with the single T958M mutants [median 7.0 nM (IQR 5.0–10.6), *P*=0.0072] (Figure 2). The double T958M-F1076L mutant parasites had a median IC_{50} of 4.4 nM (IQR 2.0–4.9), intermediate between single and triple mutants, although the differences did not reach statistical significance.

Evolution of *pvmdr1* polymorphism in Eastern Cambodia following successive changes in national treatment guidelines

The polymorphism of *pvmdr1* was then analysed according to the therapeutic strategy implemented in Eastern Cambodia. To increase the sample size and identify significant changes in frequency, we included a larger number of isolates (total *N*=301 isolates) collected in the same area between May 2014 and September 2019 for which DNA only was available. No other genotypes were observed among those additional isolates. During the period of dihydroartemisinin/piperazine deployment (2014–16), the frequency of the single mutant (T958M) was 8% (*N*=9/113). A significant increase (*P*=0.005) to 20% (*N*=38/188) was observed after adoption of artesunate/mefloquine (Figure 3). No significant difference in frequency over time was observed for the double and triple mutants. The copy number of the *pvmdr1* gene could be




Figure 1. Overall susceptibility of 52 cryopreserved Cambodian *P. vivax* isolates to chloroquine, mefloquine and piperazine measured by *in vitro* schizont maturation assays (top panel). Black circles represent individual IC₅₀ values of *P. vivax* isolates (the horizontal line shows the median and the whiskers show the IQR). For comparison, plain light blue circles represent IC₅₀ values of the susceptible *P. falciparum* 3D7 reference strain and plain dark blue circles the chloroquine or mefloquine IC₅₀ values of resistant *P. falciparum* clinical isolates. Susceptibility to chloroquine, mefloquine and piperazine of isolates collected when the first-line treatment was dihydroartemisinin/piperazine (2015–16) or artesunate/mefloquine (2017–18) (bottom panels). The susceptibility of isolates to chloroquine and piperazine significantly decreased over time (Mann–Whitney test, ** $P=0.0023$ and * $P=0.0213$, respectively). This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

determined for 241 clinical isolates and all had a single copy of the gene.

Discussion

The aim of this study was to assess the evolution of *P. vivax* in response to antimalarials used in Cambodia following the successive changes in first-line treatment. We therefore determined the *in vitro* susceptibility to drugs of cryopreserved parasites collected in Eastern Cambodia between 2015 and 2018 and tested for associations between susceptibility and polymorphisms in the *pvmdr1*

and *pvcr1* genes. Overall, no isolate showed susceptibility above the assumed resistance threshold of 220 nM chloroquine.³ Currently there is no established cut-off for piperazine or mefloquine resistance in *P. vivax*. Future studies that associate *in vitro* drug response of parasites with clinical outcomes (adequate clinical and parasitological response versus treatment failure) are needed to determine clinically relevant thresholds of resistance. However, the IC₅₀ values observed in this study are very low (median <5 nM for both mefloquine and piperazine). It is thus highly unlikely that those susceptibilities are of any therapeutic concern. Additionally, the values obtained here are among the




Figure 2. Associations between *pvmdr1* polymorphism and susceptibility to mefloquine. Median mefloquine IC_{50} s of the different genotypes are shown. Genotypes are described under each panel. Multiple comparison of mean IC_{50} of the three genotypes was assessed by the Kruskal-Wallis test and Dunn's correction. $**P < 0.01$.




Figure 3. Evolution over time of the frequency of the different *pvmdr1* genotypes among clinical isolates collected in Eastern Cambodia from 2014 to 2019. Dihydroartemisinin/piperazine was the first-line treatment from 2012 to 2016 and artesunate/mefloquine was introduced in 2017. The frequency of the less-susceptible single mutant (T958M, light blue) significantly increased from 8% to 20% after the introduction of artesunate/mefloquine treatment (Fisher's exact test, $P = 0.0050$) while no significant changes were observed for the double (T958M-F1076L, medium blue) and triple (T958M-Y976F-F1076L, dark blue) mutants. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC*.

lowest reported in the literature for Southeast Asian *P. vivax*, whether for chloroquine, mefloquine or piperazine.^{3,4,12} It should be noted that in this work we used cryopreserved isolates instead of fresh parasites, which could, in theory, have introduced some biases in the IC_{50} measurements. Future studies examining differences in IC_{50} between paired isolates determined before and after cryopreservation should be conducted to assess any effect of freeze-thaw procedures on the drug response of parasites.

Even though these parasites cannot be categorized as resistant, this study demonstrates an interesting evolution in their drug susceptibility profiles. First, *P. vivax* susceptibility to chloroquine increased significantly between 2015 and 2018, with the average IC_{50} decreasing by almost half within 4 years. This observation is consistent with the withdrawal of chloroquine from guidelines since 2012. Indeed, in a study conducted between 2008 and 2010, up to 18% of treatment failure following chloroquine treatment was reported in Eastern Cambodia, where the cryopreserved isolates used in our work originated.¹³ However, another therapeutic

efficacy study conducted in the same area, but 2 years after the replacement of chloroquine with dihydroartemisinin/piperazine, did not find any sign of treatment failure.¹⁴ Given those previous clinical results and the decrease in IC_{50} reported here, we hypothesize that there was indeed some chloroquine resistance before the change in the treatment guidelines, following which parasites gradually regained susceptibility. Importantly, none of the polymorphisms in *pvct* or *pvmdr1* detected in this work could be linked to the changes in susceptibility to chloroquine observed over time. This suggests that determinants other than *pvct* and *pvmdr1* are involved in the modulation of chloroquine susceptibility in *P. vivax*.

Because we did not identify any isolate highly resistant to chloroquine, *pvct* and *pvmdr1* polymorphisms detected in our work can definitely be excluded as markers of resistance. Other mutations in these genes (or their amplification) not observed in our study could, however, still be related to chloroquine resistance. Besides, our work cannot exclude a link between increased *pvct* expression and chloroquine resistance.⁶ Similar genotype-phenotype association studies in areas where high-grade chloroquine-resistant *P. vivax* are reported are needed to provide conclusive data on the basis of chloroquine resistance for this species.

Interestingly, the same trend for piperazine susceptibility evolution was observed, as IC_{50} s were significantly lower after artesunate/mefloquine implementation. This increase in piperazine susceptibility is probably the consequence of the withdrawal of dihydroartemisinin/piperazine as first-line treatment in the country but could also result from mefloquine pressure on parasite populations. Indeed, in *P. falciparum*, piperazine and mefloquine exert opposite pressure on parasites and increased susceptibility to piperazine is linked to decreased susceptibility to mefloquine.¹⁵ Of note, only normal dose-response curves for piperazine (and other drugs) and no paradoxical parasite growth at high drug concentrations were observed (as seen with *P. falciparum* piperazine-resistant strains), further confirming the absence of resistance of *P. vivax* in Cambodia.¹⁶

No significant evolution of mefloquine susceptibility over time was observed but polymorphism in *pvmdr1* was associated with differences in susceptibility to mefloquine. Indeed, the single T958M mutant was significantly less susceptible than the triple T958M-Y976F-F1076L mutant, though none of the isolates had an IC_{50} high enough to indicate high-grade mefloquine resistance. Additionally, the frequency of this less-susceptible T958M genotype doubled between 2015 and 2019 in Eastern Cambodia following the introduction of artesunate/mefloquine. Altogether, these results suggest ongoing selection of decreased susceptibility to mefloquine. Notably, high IC_{50} values of mefloquine were previously associated with *pvmdr1* gene amplification⁴ and parasites with multiple copies of *pvmdr1* did not carry the Y976F mutation, suggesting a fitness cost associated with having both the mutation and the gene amplification.¹⁷ In our current work, none of the isolates tested had *pvmdr1* amplification and none had high mefloquine resistance. We believe we are currently observing changes in genotypes and phenotypes predating the emergence of clinically relevant resistance to mefloquine with parasites currently losing the mutations within *pvmdr1* prior to acquiring multiple copies of the gene.

The results of this work indicate that the susceptibility of *P. vivax* parasites to antimalarials evolves in response to the drugs used in

the country. The difference with *P. falciparum* parasites from the same area is, however, striking. Indeed, while for *P. vivax* only modest changes in susceptibility were observed, for *P. falciparum* in the same time frame and the same locations, emergence of fully resistant parasites was thoroughly documented. This difference most probably results from several different factors and among these, the production of gametocytes by *P. vivax* (and its transmission to the vectors) before patients become symptomatic (and thus exposed to the drugs) certainly limits the selective pressure exerted on the parasite populations.^{18,19} In addition, a significant proportion of individuals infected by *P. vivax* are asymptomatic and therefore undetected and untreated. Despite these factors, changes in susceptibility over time and selection of specific genotypes are observed, indicating that some selective pressure does occur. This selection is probably driven by the pressure exerted by lingering antimalarials after treatment on reactivating hypnozoites during relapsing episodes. Decreased susceptibility to mefloquine would allow parasites to survive lingering subtherapeutic drug concentrations upon relapses.

In conclusion, this work warrants further monitoring of the evolution of *P. vivax* susceptibility to mefloquine and *pvmdr1* polymorphism in Cambodia in order to allow early detection of the emergence of fully resistant mefloquine isolates.

Acknowledgements

We thank all patients for participating in this study.

Funding

This study was supported by internal funding. J.P. is partly supported by the International Centers of Excellence for Malaria Research program from the National Institutes of Health, grant 1U19AI129392-0.

Transparency declarations

None to declare.

Supplementary data

Figure S1 and Tables S1 and S2 are available as [Supplementary data](#) at JAC Online.

References

- Thomson-Luque R, Adams JH, Kocken CHM *et al.* From marginal to essential: the golden thread between nutrient sensing, medium composition and *Plasmodium vivax* maturation in *in vitro* culture. *Malar J* 2019; **18**: 344.
- Popovici J, Ménard D. Challenges in antimalarial drug treatment for vivax malaria control. *Trends Mol Med* 2015; **21**: 776–88.
- Suwanarusk R, Russell B, Chavchich M *et al.* Chloroquine resistant *Plasmodium vivax*: *in vitro* characterisation and association with molecular polymorphisms. *PLoS One* 2007; **2**: e1089.
- Suwanarusk R, Chavchich M, Russell B *et al.* Amplification of *pvmdr1* associated with multidrug-resistant *Plasmodium vivax*. *J Infect Dis* 2008; **198**: 1558–64.
- Silva SR, Almeida ACG, da Silva GAV *et al.* Chloroquine resistance is associated to multi-copy *pvcr1-o* gene in *Plasmodium vivax* malaria in the Brazilian Amazon. *Malar J* 2018; **17**: 267.
- Sá JM, Kaslow SR, Moraes Barros RR *et al.* *Plasmodium vivax* chloroquine resistance links to *pvcr1* transcription in a genetic cross. *Nat Commun* 2019; **10**: 4300.
- Li J, Tao Z, Li Q *et al.* Further evaluation of the NWF filter for the purification of *Plasmodium vivax*-infected erythrocytes. *Malar J* 2017; **16**: 201.
- Russell B, Suwanarusk R, Borlon C *et al.* A reliable *ex vivo* invasion assay of human reticulocytes by *Plasmodium vivax*. *Blood* 2011; **118**: e74–81.
- Canier L, Khim N, Kim S *et al.* An innovative tool for moving malaria PCR detection of parasite reservoir into the field. *Malar J* 2013; **12**: 405.
- Urusova D, Carias L, Huang Y *et al.* Structural basis for neutralization of *Plasmodium vivax* by naturally acquired human antibodies that target DBP. *Nat Microbiol* 2019; **4**: 1486–96.
- Lu F, Lim CS, Nam DH *et al.* Genetic polymorphism in *pvmdr1* and *pvcr1-o* genes in relation to *in vitro* drug susceptibility of *Plasmodium vivax* isolates from malaria-endemic countries. *Acta Trop* 2011; **117**: 69–75.
- Chaorattanakawee S, Lon C, Chann S *et al.* Measuring *ex vivo* drug susceptibility in *Plasmodium vivax* isolates from Cambodia. *Malar J* 2017; **16**: 392.
- Leang R, Barrette A, Bouth DM *et al.* Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* in Cambodia, 2008 to 2010. *Antimicrob Agents Chemother* 2013; **57**: 818–26.
- Popovici J, Pierce-Friedrich L, Kim S *et al.* Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for *Plasmodium vivax* malaria. *J Infect Dis* 2019; **219**: 315–22.
- Witkowski B, Duru V, Khim N *et al.* A surrogate marker of piperaquine-resistant *Plasmodium falciparum* malaria: a phenotype–genotype association study. *Lancet Infect Dis* 2017; **17**: 174–83.
- Duru V, Khim N, Leang R *et al.* *Plasmodium falciparum* dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine *in vitro* assays: retrospective and prospective investigations. *BMC Med* 2015; **13**: 305.
- Auburn S, Serre D, Pearson RD *et al.* Genomic analysis reveals a common breakpoint in amplifications of the *Plasmodium vivax* multidrug resistance 1 locus in Thailand. *J Infect Dis* 2016; **214**: 1235–42.
- Bousema T, Drakeley C. Epidemiology and infectivity of *Plasmodium falciparum* and *Plasmodium vivax* gametocytes in relation to malaria control and elimination. *Clin Microbiol Rev* 2011; **24**: 377–410.
- Kitchen SF, Boyd MF. On the infectiousness of patients infected with *Plasmodium vivax* and *Plasmodium falciparum*. *Am J Trop Med Hyg* 1937; **s1-17**: 253–62.
- Roesch C, Popovici J, Bin S *et al.* Genetic diversity in two *Plasmodium vivax* protein ligands for reticulocyte invasion. *PLoS Negl Trop Dis* 2018; **12**: e0006555.